Cutaneous Leishmaniasis was affecting a great part of the population in rural areas of Venezuela, which led Dr. Convit to study the development of this disease. He performed immunological research and identified an immunological deficiency in patients affected. After the success of the Leprosy vaccine, he developed a similar highly effective immunotherapy (vaccine) for Cutaneous Leishmaniasis, which was later registered in the Sanitary Ministry of Venezuela for its mass production and distribution to specialized treatment centers throughout the country. This immunotherapy was widely used in the country, and other parts of the region, to treat patients with this disease.

Terms of Use          Privacy Policy